We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+0.87%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$3.17B
AUM Growth
-$132M
(-4%)
Cap. Flow
+$330M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
55.39%
Holding
52
New
18
Increased
15
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$125M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$110M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$94.8M |
| 4 |
ADVM
Adverum Biotechnologies
ADVM
|
+$84.8M |
| 5 |
Exelixis
EXEL
|
+$82.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$680M |
| 2 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
+$76.1M |
| 3 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$54M |
| 4 |
DVAX
Dynavax Technologies
DVAX
|
+$13.5M |
| 5 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
+$2.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRVL
26
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $39.5M | 1.25% |
3,240,534
-123,071
| -4% | -$1.96M |
|
27
Ardelyx
ARDX
$1.24B
| $36.5M | 1.15% |
6,416,684
+1,057,821
| +20% | +$7.19M |
|
28
Arcutis Biotherapeutics
ARQT
$3.26B
| $34.7M | 1.1% |
+1,165,184
| New | +$31.3M |
|
|
ADAP
29
DELISTED
Adaptimmune Therapeutics
ADAP
| $34.1M | 1.08% |
+12,541,888
| New | +$41.6M |
|
30
Crinetics Pharmaceuticals
CRNX
$8.9B
| $28.8M | 0.91% |
1,961,209
+86,000
| +5% | +$1.76M |
|
|
SCPH
31
DELISTED
scPharmaceuticals
SCPH
| $26M | 0.82% |
3,518,998
+271,993
| +8% | +$1.97M |
|
|
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
| $25.7M | 0.81% |
+6,361,446
| New | +$24M |
|
33
Stoke Therapeutics
STOK
$1.97B
| $25.6M | 0.81% |
1,119,963
| – | – |
|
34
Enliven Therapeutics
ELVN
$4.37B
| $23.3M | 0.74% |
+363,587
| New | +$23.2M |
|
35
Compugen
CGEN
$225M
| $21.5M | 0.68% |
+2,957,434
| New | +$23.2M |
|
|
IMGN
36
DELISTED
Immunogen Inc
IMGN
| $17.6M | 0.56% |
+5,166,303
| New | +$22.6M |
|
37
NovoCure
NVCR
$1.89B
| $17.4M | 0.55% |
+259,099
| New | +$20.5M |
|
|
CNCE
38
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $16.4M | 0.52% |
+1,858,474
| New | +$18.3M |
|
39
Solid Biosciences
SLDB
$849M
| $10.9M | 0.35% |
304,744
| – | – |
|
|
GRTX
40
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $8.48M | 0.27% |
893,115
-161,063
| -15% | -$2.08M |
|
41
X4 Pharmaceuticals
XFOR
$405M
| $6.02M | 0.19% |
20,076
+11,066
| +123% | +$3.14M |
|
42
Passage Bio
PASG
$14.9M
| $5.08M | 0.16% |
+16,132
| New | +$5.05M |
|
43
uniQure
QURE
$3.03B
| $3.9M | 0.12% |
+82,180
| New | +$4.72M |
|
|
EPIX
44
DELISTED
ESSA Pharma
EPIX
| $3.84M | 0.12% |
959,300
-40,700
| -4% | -$205K |
|
|
PTLA
45
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.06M | 0.1% |
429,399
| – | – |
|
46
Cartesian Therapeutics
RNAC
$237M
| $2.1M | 0.07% |
+29,021
| New | +$2.8M |
|
47
Insmed
INSM
$21.4B
| $1.4M | 0.04% |
+87,405
| New | +$2.07M |
|
48
Vericel Corp
VCEL
$2.37B
| $917K | 0.03% |
+100,000
| New | +$1.5M |
|
|
DVAX
49
DELISTED
Dynavax Technologies
DVAX
| – | – |
-2,365,912
| Closed | -$13.5M |
|
|
FTSV
50
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| – | – |
-1,933,250
| Closed | -$76.1M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, RA Capital Management held 52 positions worth $3.17B, down 4% from $3.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $330M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Adverum Biotechnologies: 727,271 shares worth $71.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier.
On the sell side, the largest reduction was Galera Therapeutics, Inc. Common Stock, an estimated $2.08M trimmed.
- RA Capital Management's largest Q1 2020 buy was Adverum Biotechnologies: 727,271 shares worth $71.1M.
- RA Capital Management added most to Axsome Therapeutics in Q1 2020, an estimated $125M increase.
- RA Capital Management's biggest Q1 2020 reduction was Galera Therapeutics, Inc. Common Stock, cutting an estimated $2.08M.
- RA Capital Management fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $680M.
- RA Capital Management's ten largest holdings make up 55% of its $3.17B portfolio in Q1 2020.
- RA Capital Management opened 18 new positions and closed 4 in Q1 2020.
- RA Capital Management's portfolio value fell 4% quarter-over-quarter to $3.17B.
Based on RA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.